The criteria for progression has stringent rules, be it single...

The criteria for progression has stringent rules, be it single or sub part divisions. That is, data analysis, peer comparatives and / or collaboration, authority approval..., etc, ect.
My post is re emphasis on the Ann re the hgc (human growth cell) part....
For a company that is on the verge of finalising it's animal model as a prerequisite of pre clinical trail structure..., the news is if the hgc addition of this pilot study is huge.
Why?.., from a licencing of parts of the sum or to even a candidate of a take over of the sum of the whole.
Interesting six months ahead with not only more collaboration results but also the deadline of pre Xmas on the Genethech deal.
Of course non of this is new, outside the possibility of timing for a TO, for most has been directly and/or indirectly implied over the past year in other Announcement or shareholders updates.
GLTAH